Key Influencer in the Epithelial Ovarian Cancer Market 2025: Rising Ovarian Cancer Prevalence To Drive Growth In The Market Driver

What Is the Forecasted Market Size and Growth Rate for the Epithelial Ovarian Cancer Market?
The market for epithelial ovarian cancer has seen quick expansion lately. Its expected to increase from $2.08 billion in 2024 to $2.42 billion in 2025, with a compound annual growth rate (CAGR) of 16.5%. The growth during the historic period is due to factors such as growing interest in personalized cancer treatments, boost in global healthcare spending, heightened demand for less invasive surgical options, increase in the number of ovarian cancer survivors, rising interest in gene therapy, and expanded demand for palliative care services.

The market for epithelial ovarian cancer is projected to witness rapid expansion in the upcoming years. The market size is expected to escalate to $4.41 billion by the year 2029 with a compound annual growth rate (CAGR) of 16.1%. The anticipated growth within this forecast period is due to factors such as the rising occurrences of ovarian cancer, a growing elderly population, increasing awareness about ovarian cancer, an escalation in cancer research funding and greater governmental initiatives battling cancer. Key trends for this forecast period involve advancements in medical imaging technology, the advent of new molecular diagnostic tools, partnerships among pharmaceutical firms, the fast-paced adoption of AI and machine learning in diagnostics, alongside widespread use of robotic surgeries.

What Factors Are Propelling the Expansion of the Epithelial Ovarian Cancer Market?
The upward trend in ovarian cancer cases is anticipated to enhance the growth of the epithelial ovarian cancer market. Ovarian cancer, predominantly affecting the epithelial cells covering the ovary* surface, is on the rise due to factors such as an aging demographic, heightened awareness, improved detection rates, as well as genetic and lifestyle elements. A significant need exists for epithelial ovarian cancer treatment to tackle this prevalent and virulent form of ovarian cancer, with the aim of targeting malignant cells to enhance survival rates and patient results. For example, the World Ovarian Cancer Coalition, a non-profit organization based in Canada, stated in February 2024 that by 2050, the number of women globally diagnosed with ovarian cancer is predicted to surge by over 55%, amounting to 503,448. The yearly fatality rate due to ovarian cancer is expected to escalate to 350,956, marking a nearly 70% rise from 2022. Hence, the escalating incidence of ovarian cancer will fuel the progress of the epithelial ovarian cancer market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp

Which Businesses Are at the Forefront of Epithelial Ovarian Cancer Market Development?
Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., Vivesto AB

How Is the Epithelial Ovarian Cancer Market Evolving?
Leading enterprises in the epithelial ovarian cancer market are investing in the creation of innovative treatment strategies, such as antibody-drug conjugates (ADCs) targeting FRa. These agents specifically bind to folate receptor-alpha abundant on cancer cells, effectively delivering cytotoxic drugs while keeping healthy tissues safe. The ADC targeted at FRa is a unique cancer treatment, which connects an antibody of the folate receptor-alpha (FRa) to a cytotoxic medicine, thereby transferring the medicine directly to cancer cells that express this receptor. For instance, in November 2024, US-based firm, AbbVie Inc. acquired approval from the European Commission for their drug ELAHERE (mirvetuximab soravtansine). This drug is a targeted remedy for adult patients with FRa positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have undergone up to three prior systemic regimens. It targets a biomarker present in roughly a third of ovarian cancer patients, boosting survival odds and improving patient lifestyles. Accompanying the approval is a companion diagnostic tool to identify suitable patients.

How Is the Epithelial Ovarian Cancer Market Segmented?
The epithelial ovarian cancer market covered in this report is segmented -

1) By Type Of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery
2) By Drug Class: Platinum-based Chemotherapy Drugs, Poly(ADP-ribose) Polymerase Inhibitors, Bevacizumab, Chemotherapeutic Agents
3) By Stage Of Cancer: Early Stage, Advanced Stage
4) By Diagnosis Method: Imaging, Biopsy, Blood Tests
5) By End User: Hospitals, Clinics, Diagnostic Laboratories

Subsegments:
1) By Chemotherapy: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Chemotherapy
2) By Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors, Other Targeted Agents
3) By Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy
4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins
5) By Surgery: Debulking Surgery, Oophorectomy, Hysterectomy, Other Surgical Procedures

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report

Where Is the Epithelial Ovarian Cancer Market Growth Most Prominent?
North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Epithelial Ovarian Cancer Global Market Report?

- Market Size Analysis: Analyze the epithelial ovarian cancer Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the epithelial ovarian cancer Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall epithelial ovarian cancer market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the epithelial ovarian cancer market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20778

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.